Lisa Hicks

🎙️ New #LungCancerVoices Podcast Out Now! @pwheatley-price & @LisaHicksMD talk about caring for socially complex individuals with cancer, social determinants of health, how poverty & inequity might impact those with a lung cancer diagnosis. Listen now at bit.ly/LCCPodcast

#IronDeficiency is common and often goes undetected. The ASH Iron Deficiency Summit convened experts to identify gaps in diagnosis, testing, to care and improve patient outcomes. hematology.org/iron-deficienc… #Hematology

It is so painful to share the news of @FralickMike sudden and unexpected passing 💔 Mike was an amazing, inspiring and generous person who touched the lives of many. As we mourn, please share and consider supporting his wife and 2-year-old daughter. gofund.me/236771146

ASH has released new Clinical Practice Guidelines on the diagnosis of light chain (AL) amyloidosis, a rare and life-threatening bone marrow disorder. The guidelines present 12 evidence-based recommendations designed to help clinicians improve diagnosis. ow.ly/OMEV50Y4S71

To the x bots bashing my poem for its format to avoid the relevancy of its content: the verse shape is inspired by Minneapolis itself. Stop griping over the structure of a poem and funnel that critical energy towards the federal agents executing American citizens.

@VincentRK This is my favourite story in medicine. So many lessons for all of us. Question dogma. Follow the evidence. Listen to patients.

I would like to share the story of how a patient with cancer came up with the idea for a randomized trial, & how listening to him saved a lot of lives. 1/ In 2002, I had just completed a randomized trial with the notorious drug thalidomide for the cancer, multiple myeloma.

From med student to fellow, Allison Taylor, MD, has received funding from ASH every step of the way! ASH can support your #hematology career, too. All you have to do is apply by Feb. 2: ow.ly/VtMh50XKYkQ #ASHAwards

Myeloma Paper of the Day, January 20th, Suggested by Robert Orlowski (@Myeloma_Doc) @JCO_ASCO @LisaHicksMD @HadidiSamer @RahulBanerjeeMD @myelomaMD @jmikhaelmd oncodaily.com/voices/myeloma… #OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #MM #Myeloma

#mmsm Every cancer deserves this level of progress (Great news to the myeloma field as well as the patients) ✅ 5-year relative survival has increased dramatically from 32% in the mid-1990s to 62% in 2015-2021 (and certainly better nowadays) ⭐️This represents one of the largest survival gains among high-mortality cancers⭐️ 🛑Estimated new cases in 2026: 36,000 total ✅ 5-year survival is virtually equal across races - 62% (White) vs 63% (Black) 👏 ⭐️One of the FEW cancers with no survival disparity, proof that when breakthrough treatments reach everyone, equity IS achievable⭐️ And yes, myeloma is a curable malignancy for some patients, the goal is to make it curable for most

Excellent to see OS benefit of CARTITUDE-4 (from #IMS24) now in @TheLancetOncol Only 2 modern Tx in MM have shown PFS, OS, & QOL ⬆️ in Ph3 trials; cilta-cel is one of them 👏 Clever Suppl Figure: almost more noticeable than if on one figure. OS best when CAR-T used early!

Treatment of Multiple Myeloma: ASCO–Ontario Health (Cancer Care Ontario) Living Guideline | Journal of Clinical Oncology @JCO_ASCO @ASCO #mmsm ➡️ ascopubs.org/doi/10.1200/JC…

Researchers at St. Michael’s Hospital found a strong association between lower-neighbourhood income and a higher risk of death after surgery, even in a universal health care system. Read the full story on our website unityhealth.to/2026/01/risk-o… @JAMANetworkOpen

Such a privilege to be on @ASCO 🇺🇸 🇨🇦 myeloma guidelines led by @LisaHicksMD @jmikhaelmd Biggest pearl 👇 Most important part of discussions about CAR-T, tec-dara, etc isn’t what I say… … it’s what patient & loved one say after I present options! No right answer for all.

Treatment of Multiple Myeloma: ASCO–Ontario Health (Cancer Care Ontario) Living Guideline | Journal of Clinical Oncology This is a living guideline 🌟 ➡️ ascopubs.org/doi/10.1200/JC… @JCO_ASCO @ASCO @HadidiSamer @jmikhaelmd @LisaHicksMD #mmsm 🧵

The myeloma world moves fast! The new ASCO-CCO Myeloma Living Guideline will be updated as the evidence evolves. Check it out. ascopubs.org/doi/10.1200/JC… @LisaHicksMD @jmikhaelmd @HiraSMian @RahulBanerjeeMD @bdermanmd @myelomaMD @SusanBal9 @MyelomaTeacher @JCO_ASCO @ASCO

Facing a difficult treatment decision in myeloma? Check out the ASCO-CCO Myeloma Treatment Guideline. ascopubs.org/doi/10.1200/JC… @jmikhaelmd @RahulBanerjeeMD @myelomaMD @HadidiSamer @HiraSMian @bdermanmd @myelomateacher

.@jmikhaelmd & @LisaHicksMD introduce a new @ASCO living guideline w/ updated recommendations for #MultipleMyeloma therapy in differing variants and pt populations. Learn more: brnw.ch/21wYSoc #mmsm

Treatment of Multiple Myeloma: ASCO–Ontario Health (Cancer Care Ontario) Living Guideline | Journal of Clinical Oncology @ASCO @JCO_ASCO #mmsm ➡️ ascopubs.org/doi/pdf/10.120… @LisaHicksMD @jmikhaelmd @HiraSMian @RahulBanerjeeMD @bdermanmd @myelomaMD @SusanBal9 @MyelomaTeacher @TomBmt133 @Ccostello7 Great team work resulted in a living guidelines for treating multiple myeloma 👇 @utswcancer @HemOncFellows @ASCOTECAG @IMFmyeloma @HealthTree

Excited for great sessions coming up at #ASH24 at the #HealthEquityStudio on advancing care for ALL patients w/ blood diseases ⁦@ASH_hematology⁩ ⁦@herandherdata⁩ ⁦@b_avalos_MD⁩ ⁦@jmikhaelmd⁩ ⁦@LisaHicksMD⁩ ⁦@LevineCancer⁩ ⁦@wakeforestmed⁩

Mike Myers playing Elon Musk on SNL and then busting out a CANADA IS NOT FOR SALE SHIRT at the end of the show is exactly the energy we need right now. 🤛❤️🇨🇦